Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

SOPHiA GENETICS (SOPH) Invested Capital (2020 - 2025)

SOPHiA GENETICS's Invested Capital history spans 6 years, with the latest figure at -$79.0 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 66.34% to -$79.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$79.0 million, a 66.34% decrease, with the full-year FY2025 number at -$79.0 million, down 66.34% from a year prior.
  • Invested Capital hit -$79.0 million in Q4 2025 for SOPHiA GENETICS, down from -$59.8 million in the prior quarter.
  • Over the last five years, Invested Capital for SOPH hit a ceiling of $50.2 million in Q2 2022 and a floor of -$87.4 million in Q4 2022.
  • Historically, Invested Capital has averaged -$30.7 million across 5 years, with a median of -$39.2 million in 2021.
  • Biggest five-year swings in Invested Capital: crashed 104.43% in 2021 and later surged 261.53% in 2022.
  • Tracing SOPH's Invested Capital over 5 years: stood at -$73.7 million in 2021, then decreased by 18.7% to -$87.4 million in 2022, then rose by 9.68% to -$79.0 million in 2023, then skyrocketed by 39.87% to -$47.5 million in 2024, then plummeted by 66.34% to -$79.0 million in 2025.
  • Business Quant data shows Invested Capital for SOPH at -$79.0 million in Q4 2025, -$59.8 million in Q3 2025, and $39.8 million in Q2 2025.